Home
TC BioPharm

TC BioPharm Market Share Analysis for March 2026

TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer.

Industry: N/A

Domaintcbiopharm.com

Year Founded2014

Employees51 - 200

Annual Revenue$2M - $5M

TC BioPharm

TC BioPharm (including company regionals)

tcbiopharm.com

See more website traffic and engagement information

TC BioPharm Revenue up to March 2026 is 2M - 5M

revenue generated by TC BioPharm top domains

TC BioPharm top domains revenue over 3 years

Revenue for TC BioPharm top domains

tcbiopharm.com2M - 5M

See more with Sales Intelligence

Total visits to TC BioPharm's top domains

Understand TC BioPharm market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

tcbiopharm.com--

See more with Sales Intelligence

Avg. visit duration in TC BioPharm's top domains

Analyze TC BioPharm engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

tcbiopharm.com--

See more with Sales Intelligence

Avg. pageviews on TC BioPharm's top domains

See how TC BioPharm keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

tcbiopharm.com--

See more with Sales Intelligence

TC BioPharm top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by TC BioPharm

These are the website technologies, by industry, used by TC BioPharm top domains

Widget (3)

Twemoji

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Content Management System (2)

WordPress

More Technologies

6

See all

News & Signals from TC BioPharm

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTC BioPharm Limited sells assets to CytoMed Therapeutics Pte Ltd.CytoMed seeks to acquire potentially synergistic assets from TC BioPharm via a cash bid to administrators, aiming to deepen its capabilities in donor-derived gamma delta T cell therapies and accelerate commercialization.

NewsTC BioPharm Limited attends event Sequire Investor Summit 2025.TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company advancing allogeneic gamma-delta T cell therapies for cancer and other diseases, announced that CEO Bryan Kobel will present a corporate overview at the Sequire Investor Summit 2025.

NewsTC BioPharm Limited receives financing of $250K in non-dilutive grant.TC BioPharm has been awarded a $250,000 non-dilutive grant from ScaleReady's G-Rex(R) Grant Program to support TCB008 manufacturing process optimizations over the next 18 months.